Altrinsic Global Advisors’s Fate Therapeutics FATE Stock Holding History

Altrinsic Global Advisors’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-27,000	Closed	-$1.58M	–	59
2021 Q4	$1.58M	Hold	27,000	–	–	0.05%	62
2021 Q3	$1.6M	Sell	27,000 -3,000	-10%	-$235K	0.05%	67
2021 Q2	$2.6M	Hold	30,000	–	–	0.08%	59
2021 Q1	$2.47M	Sell	30,000 -10,000	-25%	-$958K	0.08%	60
2020 Q4	$3.64M	Sell	40,000 -20,000	-33%	-$1.24M	0.12%	48
2020 Q3	$2.4M	Hold	60,000	–	–	0.1%	53
2020 Q2	$2.06M	Hold	60,000	–	–	0.09%	55
2020 Q1	$1.33M	Sell	60,000 -10,000	-14%	-$253K	0.07%	60
2019 Q4	$1.37M	Hold	70,000	–	–	0.06%	61
2019 Q3	$1.09M	Hold	70,000	–	–	0.05%	68
2019 Q2	$1.42M	Hold	70,000	–	–	0.07%	66
2019 Q1	$1.23M	Hold	70,000	–	–	0.06%	72
2018 Q4	$898K	Hold	70,000	–	–	0.04%	68
2018 Q3	$1.14M	Buy	70,000 +20,000	+40%	+$237K	0.05%	72
2018 Q2	$567K	Buy	+50,000	New	+$551K	0.02%	79

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Altrinsic Global Advisors's FATE Position: Q1 2022 in Review

Altrinsic Global Advisors sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 27,000 shares — an estimated $1.58M sold.

Altrinsic Global Advisors first reported a position in FATE in Q2 2018 and held it in 15 quarters. The position peaked at $3.64M in Q4 2020. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

Altrinsic Global Advisors reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
Altrinsic Global Advisors sold 27,000 Fate Therapeutics shares in Q1 2022, an estimated $1.58M.
Altrinsic Global Advisors first reported a position in Fate Therapeutics in Q2 2018 and held it in 15 quarters.
Altrinsic Global Advisors's Fate Therapeutics position peaked at $3.64M in Q4 2020.
250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Altrinsic Global Advisors's 13F filing for Q1 2022, filed 16 May 2022.